Background: Depressive symptoms (DS) can increase the risk of stroke, but it is unclear whether long-term DS trajectories are associated with incident stroke. This study aimed to explore the association of long-term DS trajectories with incident stroke.
Methods: This prospective cohort study included 11,002 adults aged 50 and older from the Health and Retirement Study during 1994-2018. DS was assessed using the 8-item version of the Center for Epidemiologic Studies Depression Scale. Stroke was obtained through self-report of doctors' diagnosis. The group-based trajectory model was used to determine DS trajectories from 1994 to 2000. Cox proportional hazard model was applied to explore the correlation of DS trajectories with incident stroke from 2000 to 2018.
Results: We identified five distinct 6-year DS trajectories. Compared with the persistent no DS trajectory, the full-adjusted HRs (95% CIs) for the persistent mild, improving, worsening, and persistent high DS trajectories were 1.15 (1.01, 1.30), 1.27 (0.88, 1.84), 1.41 (1.17, 1.71), and 1.61 (1.21, 2.16), respectively. In addition, the persistent mild DS trajectories had the largest population attributable risk percent (PAR%).
Limitations: There was a lack of information on stroke subtypes.
Conclusions: This study suggests that compared with persistent no DS, persistent mild, worsening, and persistent high DS trajectories increase the risk of stroke in the elderly. Considering that the PAR% of stroke events in the persistent mild DS trajectory is the largest, we should pay attention not only to individuals with DS, but also to those being chronically close to the cut-off value of DS.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jad.2022.04.137 | DOI Listing |
Alzheimers Dement
December 2024
The Catholic University of Korea, Seoul, Korea, Republic of (South).
Background: Women's elevated risk of Alzheimer's disease (AD) compared to men remains unclear, with gonadal hormones proposed as potential contributors. This study aimed to explore the association between follicle-stimulating hormone (FSH), estradiol (E2), neuropsychological AD stages, and cerebral Aβ deposition.
Methods: A total of 679 subjects were included in the study (N = 198 for cognitively normal (CN), N = 373 for mild cognitive impairment (MCI), and N = 108 for AD dementia groups).
Alzheimers Dement
December 2024
Carl von Ossietzky Universität Oldenburg, Oldenburg, Germany.
Background: Subjective cognitive decline (SCD) is a condition, where individuals report persistent decline of cognitive abilities, even though this decline is not detectable by neuropsychological screenings. Individuals with SCD are at a higher risk of suffering from mild cognitive impairment (MCI) and Alzheimer's disease (AD) in the future. It is important to better understand SCD to develop prevention measures, before a transition from a possible preclinical stage to MCI and AD.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
James J. Peters VA Medical Center, Bronx, NY, USA.
Background: Neuropsychiatric symptoms (NPS) are core features of Alzheimer's disease (AD) and have significant impact on patients, caregivers, and families. Worse NPS scores are associated with worse function and higher need for care. It is unclear if individual NPS symptoms may differentially affect functional decline and may be more effectively targeted to improve patient outcomes.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Calgary, Calgary, AB, Canada.
Background: Mild behavioral impairment (MBI) is a syndrome that leverages neuropsychiatric symptoms that emerge in later-life, and which persist, to identify individuals at high-risk for incident dementia. Attendant with MBI are changes in quality of life (QoL), which can present concurrent with the onset of cognitive decline or even before. Obtaining information from participants and study partners can provide a broader overview of health and QoL.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.
A critical need exists to find simpler approaches for early detection of Alzheimer disease (AD) and related dementias. These approaches must increase access to preventative interventions and treatments, both pharmacological and non-pharmacological, for people in preclinical and prodromal stages of disease. This need has been amplified by the emergence of disease modifying therapies (DMTs), which require biological confirmation of amyloid-ß positivity.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!